Skip to main content

CBD Unlimited Begins Product Launch Testing of Equine CBD Product

Written by Customer Service on . Posted in Public Companies.

CBD Unlimited’s TrailRMix Distributed for Field Study with Equine ProfessionalsCAVE CREEK, AZ, March 17, 2020 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE ‒ CBD Unlimited, Inc. (EDXC), formerly known as Endexx Corporation, a provider of innovative phytonutrient-based food and nutritional products, is pleased to announce that the first phase of product testing in field trials for its novel equine CBD product testing has officially commenced. This initial phase will examine and test the Company’s upcoming equine TrailRMix product line, which is expected to launch this year.CBD Unlimited has initiated a collaboration with veterinarians, horse caretakers, trainers and other equine experts to study the potential health benefits and applications of CBD for horses. This trial will be led by certified vets and researchers to ensure that through the testing process, the Company will determine the optimum dosage, potency and safety of the product throughout the trial’s duration.According to a study published by Market Study Report LLC., the equine supplement industry is projected to grow from 1 billion in 2018 to 1.25 billion by 2025.“This initial testing phase for our equine CBD product marks a key milestone for the Company,” commented Mr. Todd Davis, CEO and Chairman of CBD Unlimited. “We are excited to expand our animal product pipeline by providing safe and natural therapies for larger animals. We are thankful for the endless support from our development team and equine professionals who are taking the lead on this study.  Our product is formulated to optimize the delivery of CBD in to targeted areas of the body at a specific dosing range. The product is also designed to reduce irritation to the GI Tract of the horse while recovering from other conditions that cause discomfort for horses.”According to the Brightfield Group, the CBD pet market is projected to hit $1.7 Billion by 2023, and the Company strives to be at the forefront of the hemp-derived product market. CBD Unlimited has been devoted to formulating multi-spectrum hemp CBD products not only for people but for dogs and cats with its Phyto-Bites line. Following a successful roll-out of CBD pet products and showcasing at SuperZoo Expo 2019, the Company has seen an increased demand in hemp products for pets.The Company is prepared to pursue a new line of hemp products to serve the unmet need for natural and plant-based therapeutic solutions for larger animals such as horses. The “TrailRMix” line for horses will deliver the same purpose for healthful benefits that Phyto-Bytes have become known for but in formulations and concentrations specific to meet the needs of equine breeds. CBD Unlimited manufactured 800 kilos of its pellet formulation in order for equine professionals to have a substantial amount of product to test during this first trial phase.About CBD Unlimited, Inc.CBD Unlimited, Inc. develops and distributes all-natural CBD products derived from cannabis sativa plant (Hemp), containing less than 0.01% THC. Its products range from oils, capsules, topicals, and pet products, all with the shared purpose of therapeutic and pain relief for humans and pets. Phyto-Bites are CBD soft chews for animal use that are formulated to promote health and support the reduction of separation anxiety, pain, and inflammation. The science behind these products involves over half a decade of research and experiments in order to protect the accuracy in dosage and delivery of absorption per each serving.In the interest of providing conformity with federal and state mandates, the company has incorporated the “Gorilla-Tek” platform into its business practices. The Gorilla-Tek platform is the first standardized hardware agnostic and software solution that tracks high-risk, high-shrink regulated, and restricted products maintained under federal/state/local compliance. The platform provides asset protection, inventory management, compliance and an “end of sale” technology integration. Based on principles developed by the pharmacological industry, the integrated “Gorilla-Tek” platform is tremendously efficient as it provides up-to-the-minute accounting and product details. Gorilla-Tek increases productivity while reducing costs for retailers and costs in time for customers.Website: www.cbdunlimited.com  Safe Harbor NoticeThis press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the company’s business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The company undertakes no obligation to update any forward-looking statements.Contact:
For further investor and media information, contact:
CBD Unlimited, Inc.
Todd Davis
Chairman & CEO
Todd@cbdunlimited.com
480-595-6900

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.